Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications. Materials and Methods We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed. Results Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2– tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2– tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2– throughout. The HR+/HER2– to TN group had significantly poorer recurrence- free survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN through- out had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: haz- ard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2– showed improved comparable survival outcomes. Conclusion Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.
Abstract
Purpose The aim of this study was to examine molecular subtype conversions in patients who underwent neoadjuvant chemotherapy (NAC) and analyze their clinical implications. Materials and Methods We included consecutive breast cancer patients who received NAC at the National Cancer Center, Korea, between August 2002 and June 2011, and had available data on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) receptor status prior to NAC. Molecular subtypes, hormone receptor (HR) status, and ER and PR Allred scores before and after NAC were compared, and the long-term outcomes were analyzed. Results Of 322 patients, 32 (9.9%) achieved a pathologic complete response after NAC. HR+/HER2– tumors tended to convert into triple negative (TN) tumors (10.3%), whereas 34.6% of TN tumors gained HR positivity to become HR+/HER2– tumors. Clinical outcomes of molecular subtype conversion groups were compared against patients who remained as HR+/HER2– throughout. The HR+/HER2– to TN group had significantly poorer recurrence- free survival (RFS) (hazard ratio, 3.54; 95% confidence interval [CI], 1.60 to 7.85) and overall survival (OS) (hazard ratio, 3.73; 95% CI, 1.34 to 10.38). Patients who remained TN through- out had the worst outcomes (for RFS: hazard ratio, 3.70; 95% CI, 1.86 to 7.36; for OS: haz- ard ratio, 5.85; 95% CI, 2.53 to 13.51), while those who converted from TN to HR+/HER2– showed improved comparable survival outcomes. Conclusion Molecular subtypes of breast cancers changed frequently after NAC, resulting in different tumor prognostication. Tumor subtyping should be repeated after NAC in patients with breast cancer.
참고문헌 (24)
- Wolmark N, "Preoperative chemotherapy in patients with operable breast cancer : nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18", J Natl Cancer Inst Monogr, (30), pp.96~102 (2001)
- Chen AM, "Breast conservation after neoadjuvant chemotherapy : the MD Anderson Cancer Center experience", J Clin Oncol, 22, pp.2303~2312 (2004)
- Mittendorf EA, "Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy", Ann Surg, 257, pp.173~179 (2013)
- Zhang N, "The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy : a meta-analysis", Cancer Invest, 29, pp.594~598 (2011)
- van de Ven S, "Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer", Cancer Treat Rev, 37, pp.422~430 (2011)
- Tacca O, "Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy", Oncologist, 12, pp.636~643 (2007)
- Hirata T, "Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer", Br J Cancer, 101, pp.1529~1536 (2009)
- Davies C, "Long-term effects of continuing adjuvant tamoxifen to 10years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer : ATLAS, a randomised trial", Lancet, 381, pp.805~816 (2013)
- Zardavas D, "Clinical practice-changing trials : the HERA study paradigm", Expert Rev Anticancer Ther, 13, pp.1249~1256 (2013)
- Rouzier R, "Breast cancer molecular subtypes respond differently to preoperative chemotherapy", Clin Cancer Res, 11, pp.5678~5685 (2005)
- von Minckwitz G, "Selecting the neoadjuvant treatment by molecular subtype : how to maximize the benefit?", Breast, 22(Suppl 2), pp.149~151 (2013)
- Schnitt SJ., "Classification and prognosis of invasive breast cancer : from morphology to molecular taxonomy", Mod Pathol, 23(Suppl 2), pp.60~64 (2010)
- Carey LA, "Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study", JAMA, 295, pp.2492~2502 (2006)
- Onitilo AA, "Breast cancer subtypes based on ER", PR and Her2 expression : comparison of clinicopathologic features and survival, 2009, pp.7, 4~13
- 이은숙, "Locoregional Recurrence of Breast Conserving Surgery after Preoperative Chemotherapy in Korean Women with Locally Advanced Breast Cancer", Journal of Breast Cancer, 14(4), pp.289~295 (2011), 한국유방암학회
- Lee KS, "Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer:a phase II trial", Invest New Drugs, 28, pp.83~90 (2010)
- Im SA, "Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II", III breast cancer : the Korean Cancer Study Group BR 07-01, 2012, pp.132, 589~600
- Park IH, "A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer", Invest New Drugs, 30, pp.1972~1977 (2012)
- Tomasello G, "Jumping higher : is it still possible? The ALTTO trial challenge", Expert Rev Anticancer Ther, 8, pp.1883~1890 (2008)
- Kaufmann M, "Recommendations from an international expert panel on the use of neoadjuvant(primary)systemic treatment of operable breast cancer : an update", J Clin Oncol, 24, pp.1940~1949 (2006)
- Chen S, "Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer", Ann Surg Oncol, 19, pp.3002~3011 (2012)
- Voduc KD, "Breast cancer subtypes and the risk of local and regional relapse", J Clin Oncol, 28, pp.1684~1691 (2010)
- Houssami N, "Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy", Eur J Cancer, 48, pp.3342~3354 (2012)
- Kawajiri H, "Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer", Oncol Lett, 7, pp.663~668 (2014)